Schrier Robert W, Estacio Raymond O, Mehler Philip S, Hiatt William R
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA.
Nat Clin Pract Nephrol. 2007 Aug;3(8):428-38. doi: 10.1038/ncpneph0559.
The hypertensive and normotensive Appropriate Blood Pressure Control in Diabetes (ABCD) studies were prospective, randomized, interventional clinical trials with 5 years of follow-up that examined the role of intensive versus standard blood pressure control in a total of 950 patients with type 2 diabetes mellitus. In the hypertensive ABCD study, a significant decrease in mortality was detected in the intensive blood pressure control group when compared with the standard blood pressure control group. There was also a marked reduction in the incidence of myocardial infarction when patients were randomly assigned to initial antihypertensive therapy with angiotensin-converting-enzyme inhibition rather than calcium channel blockade. The results of the normotensive ABCD study included associations between intensive blood pressure control and significant slowing of the progression of nephropathy (as assessed by urinary albumin excretion) and retinopathy, and fewer strokes. In both the hypertensive and normotensive studies, mean renal function (as assessed by 24 h creatinine clearance) remained stable during 5 years of either intensive or standard blood pressure intervention in patients with normoalbuminuria (<30 mg/24 h) or microalbuminuria (30-300 mg/24 h) at baseline. By contrast, the rate of creatinine clearance in patients with overt diabetic nephropathy (>300 mg/24 h; albuminuria) at baseline decreased by an average of 5 ml/min/year in spite of either intensive or standard blood pressure control. Analysis of the results of 5 years of follow-up revealed a highly significant correlation of all-cause and cardiovascular mortality with left ventricular mass and severity of albuminuria.
高血压和血压正常的糖尿病患者适度血压控制(ABCD)研究是前瞻性、随机、干预性临床试验,随访期为5年,研究了强化血压控制与标准血压控制在总共950例2型糖尿病患者中的作用。在高血压ABCD研究中,与标准血压控制组相比,强化血压控制组的死亡率显著降低。当患者被随机分配接受血管紧张素转换酶抑制剂而非钙通道阻滞剂进行初始抗高血压治疗时,心肌梗死的发生率也显著降低。血压正常的ABCD研究结果包括强化血压控制与肾病进展显著减缓(通过尿白蛋白排泄评估)和视网膜病变之间的关联,以及中风减少。在高血压和血压正常的研究中,对于基线时尿白蛋白正常(<30 mg/24 h)或微量白蛋白尿(30 - 300 mg/24 h)的患者,在强化或标准血压干预的5年期间,平均肾功能(通过24小时肌酐清除率评估)保持稳定。相比之下,尽管进行了强化或标准血压控制,基线时患有显性糖尿病肾病(>300 mg/24 h;蛋白尿)的患者肌酐清除率平均每年下降5 ml/min。对5年随访结果的分析显示,全因死亡率和心血管死亡率与左心室质量和蛋白尿严重程度高度相关。